Current Report Filing (8-k)
September 27 2016 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 21, 2016
STELLAR BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in
its charter)
British Columbia, Canada
|
000-54598
|
N/A
|
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
332 E. Scott Street
Port Hueneme, California 93041
(Address of principal executive offices)
(Zip Code)
(805) 488-2800
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On
September 21, 2016, Mark McPartland, Vice President of Corporate Development and Communications of Stellar Biotechnologies, Inc.
(the “Company”), notified the Company that he will resign from his position effective September 29, 2016. Mr. McPartland
is resigning to pursue a new business opportunity. His decision was not due to any disagreement with the Company on any matter
relating to the Company’s operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Stellar Biotechnologies, Inc.
|
|
|
|
|
|
|
Date: September 27, 2016
|
By:
|
/s/
Kathi Niffenegger
|
|
Name:
|
Kathi Niffenegger
|
|
Title:
|
Chief Financial Officer
|
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024